LMTK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
K-252A (SCHEMBL968886)	1.00	2/20
K-252A (SCHEMBL1982253)	1.00	2/20
SCHEMBL5951557	1.00	2/20
Cep-1347 (SCHEMBL8263437)	0.74	2/20
SCHEMBL8230031	0.65	2/20
SCHEMBL7246631	0.44	2/20
SCHEMBL7246633	0.44	2/20
Bromide (SCHEMBL7245256)	0.42	2/20
Bromide (SCHEMBL7245264)	0.42	2/20
Gf-109203 (SCHEMBL338086)	1.00	1/20
Gf-109203 (SCHEMBL1199513)	0.98	1/20
SCHEMBL7823516	0.88	1/20
SCHEMBL7826095	0.81	1/20
SCHEMBL7199461	0.81	1/20
SCHEMBL7815621	0.81	1/20
SCHEMBL7822724	0.81	1/20
SCHEMBL7823303	0.81	1/20
SCHEMBL9083061	0.81	1/20
SCHEMBL9084087	0.81	1/20
SCHEMBL9084210	0.81	1/20

Clinical trials — most relevant to LMTK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Effect of Silymarin in Metastatic Colorectal Cancer Patients	PHASE3	UNKNOWN
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer	PHASE2	RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer	PHASE2	COMPLETED
A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement	PHASE2	UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors	PHASE1	UNKNOWN
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)	PHASE1	COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a LMTK3 binder may also engage these)

Protein	Name	Similarity
Q5XJV6	—	1.000	Q5XJV6 →
Q80UE6	—	0.997	Q80UE6 →
Q96J92	—	0.995	Q96J92 →
Q8C1M2	—	0.995	Q8C1M2 →
TESK1	Dual specificity testis-specific protein kinase 1	0.994	landscape →
A8MVW0	—	0.994	A8MVW0 →
Q9DF69	—	0.994	Q9DF69 →
D3ZG83	—	0.993	D3ZG83 →
O43638	—	0.992	O43638 →
Q10586	—	0.992	Q10586 →
Q5TGY3	—	0.992	Q5TGY3 →
Q8NDX1	—	0.992	Q8NDX1 →
Q7TPK6	—	0.992	Q7TPK6 →
Q8BLR5	—	0.992	Q8BLR5 →
Q80YF9	—	0.991	Q80YF9 →
Q8VDG6	—	0.991	Q8VDG6 →
A2AEV7	—	0.991	A2AEV7 →
Q8VHQ2	—	0.991	Q8VHQ2 →
D4A9R4	—	0.991	D4A9R4 →
A0A8I3PMN2	—	0.991	A0A8I3PMN2 →
Q3KP66	—	0.991	Q3KP66 →
Q96RK0	—	0.991	Q96RK0 →
Q2M3G4	—	0.991	Q2M3G4 →
Q61501	—	0.990	Q61501 →
P19419	—	0.990	P19419 →
Q6AY88	—	0.990	Q6AY88 →
Q7Z6I6	—	0.990	Q7Z6I6 →
Q8NHY3	—	0.990	Q8NHY3 →
Q3TY92	—	0.990	Q3TY92 →
Q63572	—	0.990	Q63572 →